Parathyroid Hormone Market Report 2025 (Global Edition)

Global Parathyroid Hormone Market Report 2024 Market Size Split by Disease Type (Hypocalcemia, Hypoparathyroidism), by Product Type (Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues), by...

Parathyroid Hormone Market Report Description

We have various report editions of Parathyroid Hormone Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Parathyroid Hormone Market Insights Video

Competitive Landscape of the Parathyroid Hormone Market

The parathyroid hormone (PTH) market features a competitive landscape dominated by major pharmaceutical companies like Amgen, Novo Nordisk, and Eli Lilly. Key players focus on developing advanced PTH therapies, including treatments for osteoporosis and hypoparathyroidism. Innovation and strategic partnerships are crucial for market positioning. Competitive dynamics are influenced by factors such as product efficacy, regulatory approvals, and market expansion efforts. Companies are also investing in research to address unmet medical needs and enhance treatment outcomes.

In November 2022, Amolyt Pharma announced an oral presentation at the 25th European Congress of Endocrinology (ECE) 2023, highlighting the potential advantages of eneboparatide as a treatment for hypoparathyroidism. This condition often leads to or increases the risk of developing osteopenia and osteoporosis in many individuals. (Source: https://amolytpharma.com/wp-content/uploads/2023/05/2023-05-11-Amolyt-Oral-Presentation-@-ECE-FINAL-English.pdf ) In August 2021, Enzene Biosciences Ltd has been granted Marketing Authorization by the Drug Controller General of India for its biosimilar denosumab, which is used for treating osteoporosis in adults. (Source: https://www.prnewswire.com/in/news-releases/enzene-biosciences-ltd-obtains-a-marketing-authorization-for-its-denosumab-biosimilar-drug-in-india-821614403.html#:~:text=PUNE%2C%20India%2C%20Aug.,treatment%20of%20osteoporosis%20in%20adults. ) In January 2021, Theramex, a pharmaceutical company based in London, has introduced the osteoporosis medication Livogiva in Europe. (Source: https://www.theramex.com/news/theramex-launches-livogiva/ )

Top Companies Market Share in Parathyroid Hormone Industry: (In no particular order of Rank)

• Amgen Inc.
• Novo Nordisk A/S
• Sanofi S.A.
• Ipsen Pharma
• Eli Lilly and Company
• Teriparatide
• Bristol-Myers Squibb Company
• NantKwest
• Inc.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• GSK
• Allergan plc
• AbbVie Inc.
• Roche Holding AG
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Parathyroid Hormone Market

Which Region Dominates the Parathyroid Hormone Market in 2024?

According to Cognitive Market Research, North America holds the largest market share in the parathyroid hormone (PTH) market due to advanced healthcare infrastructure, high prevalence of osteoporosis, and strong demand for innovative therapies. The region benefits from significant research and development investments, robust regulatory frameworks, and high healthcare expenditure. Additionally, major pharmaceutical companies and a well-established distribution network contribute to market dominance. Increased awareness and early diagnosis further drive the demand for PTH treatments in North America.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific region is experiencing the fastest CAGR in the parathyroid hormone (PTH) market due to rising awareness of osteoporosis and other related conditions, coupled with improving healthcare infrastructure. Growing urbanization, increasing healthcare expenditure, and a rising elderly population contribute to the demand for advanced PTH therapies. Additionally, expanding pharmaceutical markets and regulatory support for new treatments are driving growth. The region’s economic development and increasing access to medical care further support the market’s rapid expansion.

The current report Scope analyzes Parathyroid Hormone Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Parathyroid Hormone Market

According to Cognitive Market Research, the global Parathyroid Hormone market size was estimated at USD 2458.50 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 983.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Parathyroid Hormone market with a market size of USD 775.90 million in 2024 and is projected to grow at a CAGR of 2.0% during the forecast period. The U.S. market's advanced healthcare infrastructure, high prevalence of bone disorders, and significant investment in research and development is driving the Parathyroid Hormone market.
• The Canada Parathyroid Hormone market had a market share of USD 118.01 million in 2024 and is projected to grow at a CAGR of 3.0% during the forecast period. Canada’s strong focus on early diagnosis and management of conditions like osteoporosis and hypoparathyroidism is driving the Parathyroid Hormone market.
• The Mexico Parathyroid Hormone market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 89.49 million in 2024.

Europe Parathyroid Hormone Market

According to Cognitive Market Research, the global Parathyroid Hormone market size was estimated at USD 2458.50 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 737.55 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.5% from 2024 to 2031.

• The United Kingdom Parathyroid Hormone market had a market share of USD 123.91 million in 2024 and is projected to grow at a CAGR of 3.3% during the forecast period. In the UK, Parathyroid Hormone sales witness an upswing due to strong emphasis on advanced healthcare and early diagnosis of bone disorders.
• The France Parathyroid Hormone market is projected to witness growth at a CAGR of 1.7% during the forecast period, with a market size of USD 67.85 million in 2024.
• According to Cognitive Market Research, the German Parathyroid Hormone market size was valued at USD 146.03 million in 2024 and is projected to grow at a CAGR of 2.7% during the forecast period. In Germany, Parathyroid Hormone surged due to presence of major market players.
• The Italy Parathyroid Hormone market is projected to witness growth at a CAGR of 1.9% during the forecast period, with a market size of USD 63.43 million in 2024.
• The Russia Parathyroid Hormone market is projected to witness growth at a CAGR of 1.5% during the forecast period, with a market size of USD 114.32 million in 2024.
• The Spain Parathyroid Hormone market is projected to witness growth at a CAGR of 1.6% during the forecast period with a market size of USD 60.48 million in 2024
• The Luxembourg Parathyroid Hormone market is projected to witness growth at a CAGR of 2.6% during the forecast period, with a market size of USD 22.86 million in 2024.
• The Portugal Parathyroid Hormone market is projected to witness growth at a CAGR of 2.3% during the forecast period, with a market size of USD 15.49 million in 2024.
• The Greece Parathyroid Hormone market is projected to witness growth at a CAGR of 2.8% during the forecast period, with a market size of USD 8.85 million in 2024.
• The Rest of Europe's Parathyroid Hormone market is projected to witness growth at a CAGR of 1.2% during the forecast period, with a market size of USD 114.32 million in 2024.

Asia Pacific Parathyroid Hormone Market

According to Cognitive Market Research, the global Parathyroid Hormone market size was estimated at USD 2458.50 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 565.46 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Parathyroid Hormone market size was valued at USD 254.45 million in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period. Parathyroid Hormone surged in China due to rising healthcare access, increasing awareness of bone disorders, and a large aging population.
• The Japan Parathyroid Hormone market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD 78.03 million in 2024.
• The India Parathyroid Hormone market had a market share of USD 67.85 million in 2024 and is projected to grow at a CAGR of 7.8% during the forecast period. India's rising disposable incomes is driving the Parathyroid Hormone market.
• The South Korean Parathyroid Hormone market is projected to witness growth at a CAGR of 5.1% during the forecast period, with a market size of USD 56.55 million in 2024.
• The Australian Parathyroid Hormone market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 29.40 million in 2024.
• The South East Asia Parathyroid Hormone market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 39.02 million in 2024.
• The Rest of Asia Pacific Parathyroid Hormone market is projected to witness growth at a CAGR of 5.8% during the forecast period, with a market size of USD 40.15 million in 2024.

South America Parathyroid Hormone Market

According to Cognitive Market Research, the global Parathyroid Hormone market size was estimated at USD 2458.50 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 122.93 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Parathyroid Hormone market size was valued at USD 52.61 million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. Parathyroid Hormones flourished in Brazil due to increasing healthcare access, rising awareness of bone disorders, and expanding medical infrastructure.
• Argentina's Parathyroid Hormone market had a market share of USD 20.65 million in 2024 and is projected to grow at a CAGR of 4.3% during the forecast period. Argentina's improve diagnosis and treatment options is driving the Parathyroid Hormone market.
• Colombia Parathyroid Hormone market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD 10.94 million in 2024.
• Peru Parathyroid Hormone market is projected to witness growth at a CAGR of 3.6% during the forecast period, with a market size of USD 10.08 million in 2024.
• Chile Parathyroid Hormone market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 8.85 million in 2024.
• The Rest of Latin America's Parathyroid Hormone market is projected to witness growth at a CAGR of 2.5% during the forecast period, with a market size of USD 19.79 million in 2024.

Middle East and Africa Parathyroid Hormone Market

According to Cognitive Market Research, the global Parathyroid Hormone market size was estimated at USD 2458.50 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 49.17 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031..

• The GCC Countries Parathyroid Hormone market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD 21.04 million in 2024. Parathyroid Hormone sales flourish due to the presence of major market players.
• The Egypt Parathyroid Hormone market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 5.16 million in 2024.
• The South Africa Parathyroid Hormone market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 7.77 million in 2024. Parathyroid Hormone sales flourished in South Africa due to increasing awareness and diagnosis of bone disorders, expanding healthcare infrastructure, and rising investments in medical advancements.
• The Turkey Parathyroid Hormone market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD 4.23 million in 2024.
• The Nigeria Parathyroid Hormone market is projected to witness growth at a CAGR of 2.8% during the forecast period, with a market size of USD 5.16 million in 2024.
• The Rest of the MEA Parathyroid Hormone market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 5.80 million in 2024.

Parathyroid Hormone Market Analysis

Parathyroid Hormone Market Disease Type Segment Analysis

According to Cognitive Market Research, Hypocalcemia Parathyroid Hormones are likely to dominate the Parathyroid Hormone Market over the forecast period. Hypocalcemia disease type holds the largest market share in the parathyroid hormone (PTH) market due to its high prevalence and significant impact on patients' quality of life. The condition often requires ongoing treatment, driving demand for effective PTH therapies. Additionally, the increased recognition of hypocalcemia’s role in various health issues, such as bone disorders, and advancements in treatment options contribute to its dominant market position. The ongoing need for management and monitoring of this condition sustains market growth.

Hypoparathyroidism is growing at the highest CAGR in the parathyroid hormone (PTH) market due to rising awareness and improved diagnosis of the condition. Advances in PTH therapies and increased research into effective treatments drive market expansion. The growing prevalence of hypoparathyroidism, coupled with heightened patient and healthcare provider awareness, contributes to the increasing demand for specialized treatments. Additionally, the development of new and innovative therapies enhances treatment options, fueling market growth in this segment.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Parathyroid Hormone Industry. Request a Free Sample PDF!

Parathyroid Hormone Market Product Type Segment Analysis

According to Cognitive Market Research, the Recombinant Parathyroid Hormone segment holds the largest share of the market. Recombinant parathyroid hormone (PTH) products capture the largest market share due to their high efficacy and targeted action in treating conditions like osteoporosis and hypoparathyroidism. These products offer advanced therapeutic benefits over traditional treatments, including improved patient outcomes and fewer side effects. The growing adoption of recombinant PTH is driven by its superior safety profile, extensive clinical evidence, and ongoing research and development that enhance its effectiveness. This positions recombinant PTH as a preferred choice in the market.

Parathyroid hormone analogues are growing at the highest CAGR in the parathyroid hormone market due to their enhanced therapeutic profiles and specific targeting of bone disorders like osteoporosis. These analogues offer improved efficacy, reduced side effects, and better patient compliance compared to conventional treatments. Advances in formulation and increasing clinical evidence supporting their benefits drive their adoption. Additionally, their ability to address unmet medical needs and ongoing research into new analogues contribute to their rapid market growth.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Parathyroid Hormone End-user Segment Analysis

Parathyroid Hormone Market End-user Segment Analysis

According to Cognitive Market Research, the Hospitals segment dominates the market. Hospitals capture the largest market share in the parathyroid hormone (PTH) market due to their comprehensive diagnostic and treatment capabilities. Hospitals are equipped with advanced medical technologies and specialized staff, enabling them to manage complex conditions like osteoporosis and hypoparathyroidism effectively. They also handle a significant volume of patients requiring PTH therapies, which drives demand. Additionally, hospitals often have the infrastructure to administer and monitor PTH treatments, contributing to their dominant position in the market.

Clinics are growing at the highest CAGR in the parathyroid hormone (PTH) market due to their increasing role in providing specialized, outpatient care. The rise in preventive and routine treatments for conditions like osteoporosis and hypoparathyroidism is driving this growth. Clinics offer convenient access, personalized care, and often have more flexible treatment schedules, appealing to patients seeking ongoing management. Additionally, advancements in diagnostic and treatment technologies at clinics enhance their ability to effectively manage PTH therapies, further fueling their expansion.

• Hospitals
• Clinics
• Other End-Users

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion